Supported by:
Wednesday, August 27th
Welcome address and opening remarks
Keynote lecture
Session 1 : Phospholipases A2 and acyltransferases
Session 2: Cyclooxygenases and prostanoid receptors
Thursday, August 28th
Session 3: NSAIDs, coxibs, and beyond
Session 4: Novel sources of lipid mediators
Session 5: Lipoxygenases and leukotrienes
Session 6: Lipoxygenases and leukotrienes, clinical applicationsSession 7: Novel mediators in resolution of inflammation
Session 8: Sphingolipids, from inborn neurodegenerative disorders to inflammation
Session 9: Personal reflections, special episodes and memories
11.30-13.00 Lunch at Nobel Forum
13.00-13.10 Welcome address and opening remarks
Anders Hamsten & Jesper Z. Haeggström13.10-14.00 Key Note Lecture
Bengt SamuelssonSession 1: Phospholipases A2 and acyltransferases Chairpersons: Hans-Erik Claesson & Carol Rouzer
14.00-14.30 PLA2, structures, mechanisms and membrane interactions
Edward A. Dennis14.30-15.00 Characterization of lysophospholipid acyltransferase in vitro and in vivo
Takao Shimizu15.00-15.30 Novel biological functions of PLA2
Makoto Murakami15.30-16.00 Coffee break
Session 2: Cyclooxygenases and prostanoid receptors Chairpersons: Mats Hamberg & Per-Johan Jakobsson
16.00-16.30 COX-1 and COX-2
William L. Smith16.30-17.00 Prostanoid receptors
Shuh Narumiya
Session 3: NSAIDs, coxibs, and beyond
Chairpersons: Paola Patrignani & Volker Ullrich09.00-09.30 Pharmacology of aspirin and other NSAIDs
Carlo Patrono09.30-10.00 Novel COX products and therapeutic
opportunities
Lawrence J. Marnett10.00-10.30 Coffee break
Session 4: Novel sources of lipid mediators
Chairpersons: Angelo Sala & Ernst Oliw10.30-11.00 Mass spectrometry of oxylipins, past, present, and future
Robert C. Murphy11.00-11.30 Esterified oxylipins
Valerie O’Donnell
11.30-12.30 Lunch
Session 5: Lipoxygenases and leukotrienes
Chairpersons: G. Enrico Rovati & Nicolas Flamand12.30-13.00 5-lipoxygenase
Colin D. Funk13.00-13.30 Receptors for leukotriene B4
Takehiko Yokomizo13.30-14.00 Cysteinyl-leukotrienes, enzymes and novel receptors
K. Frank Austen14.00-14.30 Coffee break
Session 6: Lipoxygenases and leukotrienes, clinical applications
Chairpersons: Giancarlo Folco & Olof Rådmark
14.30-15.00 Leukotrienes and prostaglandins as targets for treatment of asthma
Sven-Erik Dahlén15.00-15.30 12R- lipoxygenase, a key role in human ichthyosis
Alan R. Brash15.30-16.00 Enzymes in the leukotriene cascade, novel therapeutic opportunities
Jesper Z. Haeggström
Session 7: Novel mediators in resolution of inflammation
Chairpersons: Jan Palmblad & Kenneth Honn09.00-09.30 Omega-3 fatty acids and synthesis of proresolving mediators
Charles N. Serhan09.30-10.00 Proresolving lipid mediators in asthma
Bruce Levy10.00-10.30 Lipid mediators in vision and neuroprotection
Nicolas G. Bazan10.30-11.00 Coffee break
Session 8: Sphingolipids, from inborn neurodegenerative disorders to inflammation
Chairpersons: Yusuf Hannun & Josef Pfeilschifter
The session is sponsored by:
11.00-11.30 Discovery and bioactions of sphingosine-1-phosphate
Sarah Spiegel11.30-12.00 Sphingosine kinases
Lina M. Obeid12.00-13.00 Lunch
13.00-13.30 Receptors for sphingosine-1-phosphate
Timothy Hla13.30-14.00 Animal models for sphingolipid deficiency
Richard L. Proia14.00-14.30 Fingolimod, a first line drug for treatment of MS
Volker Brinkmann
Session 9: Personal reflections, special episodes and memories
14.30-15.15 John A. Oates, William Lands, Nicolas G. Bazan, Sven-Erik Dahlén, Robert C. Murphy, Takao Shimizu & Gerald Weissman
15.15- Concluding remarks
Jesper Z. Haeggström, Tim Hla, Charles N. Serhan & Takao Shimizu
VENUE